Eiger BioPharmaceuticals, Inc.
EIGR
Classement en actions
#36446
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Prix de l'action
$1.73
Dernière synchronisation: 2025-06-17
Capitalisation boursière
$2.55M
Changement (1 jour)
-0.29%
Changement (1 an)
-79.71%
Pays
US
Échange Eiger BioPharmaceuticals, Inc. (EIGR)
Catégorie
Healthcare
EPS pour Eiger BioPharmaceuticals, Inc. (EIGR)
EPS au December 2023 TTM : $-50.79
Selon les derniers rapports financiers et le cours de l'action de Eiger BioPharmaceuticals, Inc., l’EPS actuel de la société (TTM) est de $-50.79. À la fin de 2022, la société avait un EPS de $-69.74 une augmentation par rapport à celui de 2021, qui était de $-29.98.
Historique de l'EPS de Eiger BioPharmaceuticals, Inc. de 2016 à 2026
EPS à la fin de chaque année
| Année | EPS | Changez |
|---|---|---|
| 2026 (TTM) | $-50.79 | 0.02% |
| 2023 | $-50.78 | -27.19% |
| 2022 | $-69.74 | 132.62% |
| 2021 | $-29.98 | -56.76% |
| 2020 | $-69.34 | -25.04% |
| 2019 | $-92.50 | -19.31% |
| 2018 | $-114.63 | -21.43% |
| 2017 | $-145.90 | -37.96% |
| 2016 | $-235.16 | 0.00% |
EPS pour des entreprises ou concurrents similaires
| Entreprise | EPS | Différence d’EPS | Pays |
|---|---|---|---|
| $17.32 | -134.10% |
US
|
|
| $-7.98 | -84.29% |
US
|
|
| $-5.29 | -89.58% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -154.62% |
NL
|
